EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Projecting the United States ESRD population: issues regarding treatment of patients with ESRD



Projecting the United States ESRD population: issues regarding treatment of patients with ESRD



Kidney International. Supplement 2004(90): S3-S7



In 2001, there were 406,081 patients who received treatment for end-stage renal disease (ESRD), increasing by 4.2% since 2000. The number of patients with ESRD has grown consistently over the past decade, with the greatest rate of growth occurring among patients older than 75 years of age, and patients with comorbidities such as diabetes mellitus and hypertension. Current projections indicate that the population of patients with ESRD may reach more than 2 million by 2030. The overall mortality rate has fallen by 10% since 1988, with the greatest decline among patients incident to dialysis, and an increase among patients receiving dialysis for greater than five years. While the rate of hospitalization for ESRD patients has remained relatively constant, recent improvements in mortality are temporally associated with a greater proportion of patients achieving adequate benchmarks of care in dialytic processes, such as anemia correction and dose of dialysis. The ESRD program consumes 6.4% of the Medicare budget. On a per-patient per month basis, Medicare costs have risen between 1991 and 2001. While payments fell slightly during 1998 and 1999 because of changes in Medicare policies, more recent years have seen an upswing in total expenditures, presumably related to use of injectables not included in the composite rate. Continued growth in the number of new patients reaching ESRD, as well as improved mortality rates of ESRD patients, are both contributing to the current rise and projected epidemic of ESRD over the next 25 years. The current public health strategy of identification of patients with early kidney disease to slow their progression to ESRD, in addition to aggressive treatment strategies to minimize the morbidity and mortality of patients with ESRD, is essential toward affecting the growth and health of this population.

(PDF emailed within 0-6 h: $19.90)

Accession: 012456940

Download citation: RISBibTeXText

PMID: 15296500

DOI: 10.1111/j.1523-1755.2004.09002.x



Related references

Impact of timing of nephrology referral and pre-ESRD care on mortality risk among new ESRD patients in the United States. American Journal of Kidney Diseases 41(2): 310-318, 2003

Association of Pre-ESRD Serum Calcium with Post-ESRD Mortality Among Incident ESRD Patients: a Cohort Study. Journal of Bone and Mineral Research, 2018

Survival trends in ESRD patients compared with the general population in the United States. American Journal of Kidney Diseases 63(3): 491-499, 2014

Methodological limitations of the ESRD Core Indicators Project: an ESRD network's experience with implementing an ESRD quality survey. Medical Review Board of the ESRD Network of New England. American Journal of Kidney Diseases 30(3): 349-355, 1997

Treatment modalities for ESRD patients. United States Renal Data System. American Journal of Kidney Diseases 32(2 Suppl 1): S50-S59, 1998

Projecting the US ESRD population to 2030. Journal of the American Society of Nephrology 14(Abstracts Issue): 255A, November, 2003

Quantity and quality of ESRD treatment in the United States of America. Contributions to Nephrology 78: 181-185, 1990

The increasing burden of diabetes in United States ESRD patients. Journal of the American Society of Nephrology 13(Program and Abstracts Issue): 646A, September, 2002

ESRD and Hospice Care in the United States: Are Dialysis Patients Welcome?. American Journal of Kidney Diseases, 2018

Minorities and ESRD. Part II. Tracking causes of ESRD in the Hispanic population. Nephrology News & Issues 9(10): 13, 16-13, 16, 1995

Minorities and ESRD. Part I. Tracking the causes of ESRD in the Hispanic population. Nephrology News & Issues 9(9): 34-34, 1995

Determinants and prognostic importance of cardiomegaly among new ESRD patients in the United States. Annals of Epidemiology 14(9): 676-685, 2004

Effectiveness of nutrition interventions in the pre-ESRD and the ESRD population. American Journal of Kidney Diseases 32(6 Suppl 4): S126-S130, 1999

Hispanic ethnicity and risk of cause-specific death among new ESRD patients in the United States. Journal of the American Society of Nephrology 14(Abstracts Issue): 715A, November, 2003

Survival differences between hemodialysis and peritoneal dialysis among large ESRD patients in the United States. Journal of the American Society of Nephrology 14(Abstracts Issue): 500A, November, 2003